Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Indian Refiners Scale Back Russian Oil Imports as U.S.-India Trade Deal Advances 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
SpaceX Pivots Toward Moon City as Musk Reframes Long-Term Space Vision 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Celltrion just completed the phase 3 trial for its COVID-19 antibody treatment and it has shown very positive results. The biopharmaceutical company headquartered in Incheon, South Korea proves the efficacy of its treatment and full phase 3 results will follow before this month ends.
Outcome of phase 3 tests for the new COVID-19 antibody treatment
Celltrion said on Monday, June 14, that phase 3 of the clinical study for its Rekirona, yielded good results. This means that it was proven to be safe and effective after being tested with volunteer patients from 13 countries worldwide.
As per The Korea Herald, 1,315 patients took part in the third phase trial for Rekirona or CT-P59. The tests were conducted between the months of January and April of this year.
The South Korean biotech company stated that the treatment is effective and significantly reduced the recovery time and rate of progression for acute symptoms of COVID-19. Celltrion discovered through the phase 3 trial that the risk of cases progressing to a severe condition of coronavirus infection was reduced by 70%. In the high-risk group of patients, the progression rate to severe stage was said to have been cut by 72%.
What’s more, those treated with Celltrion’s Rekirona also showed significant results in recovery time as it was shortened. It was said that recovering from the disease was 4.7 to 4.9 days faster compared to others who used other treatments, Yonhap News Agency reported.
Most importantly, it was reported that the Celltrion COVID-19 antibody treatment did not show any serious adverse reaction. Only mild and temporary reactions were noted on the patients during the trial.
Celltrion’s shares surge after Celltrion’s phase 3 trial results were announced
Meanwhile, Pulse News reported that Celltrion’s shares increased by 5.08 percent to ₩279,000 or around $249.69 after the phase 3 test results for Rekirona were revealed. Celltrion Pharm, the company’s drug developing unit’s shares also went up by 12.54 percent to ₩156,200 while Celltrion Healthcare’s shares surged to 5.02 percent to ₩123,500.
In any case, Celltrion will now use the good results to seek marketing approval for the Covid-19 therapy in the U.S. The company will submit the documents to the U.S. Food and Drug Administration and the European Medicines Agency so it can be allowed to sell the treatment in the said regions.
